The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Vanda Pharmaceuticals received FDA approval for Nereus for motion sickness, and its shares offer upside potential into 2026 ...

The reforms have helped improve the domestic healthcare system by enabling pharma firms to overcome a medicine shortage ...

Elon Musk's Neuralink plans to start high-volume production of brain-computer interface devices in 2026, utilizing automated ...

Habil F Khorakiwala, Founder and Chairman of the Wockhardt Group, said the company has around ₹1,700 crore in debt but has no ...

New faces and those familiar in terms of celebrities made up some memorable moments in 2025. In addition, there were local ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

Barron’s consistently favored equities over bonds for income in the past decade, and we’re sticking with that bias in the new ...

THE People’s Progressive Party extends warm New Year’s greetings to all Guyanese at home and across the Diaspora as we welcome 2026 with renewed faith, hope, ...

Elon Musk's Neuralink plans to start high-volume production of brain-computer interface devices in 2026, utilizing automated procedures. The device, implanted in 12 individuals so far and is currently ...